Proteomics

Dataset Information

0

PC4 is a post-transcriptional manipulator of D-type cyclins and centromere proteins


ABSTRACT: The cell cycle is an intensively control process, in which cell-cycle proteins display a cyclical expression pattern regulated by specific transcription, translation and degradation. Cell cycle progression is initiated by highly expressed D-type cyclins (D1/2/3) to facilitate DNA synthesis, subsequently driven by mitotic proteins formation (e.g., centromere proteins) that is responsible for mitosis onset. Whether there exist master regulators to keep the cycle rapidly “running” with D-type cyclins induction, as well as maintain the cycle in a stable process by centromere proteins modulation is of particular interest yet remains unclear at present. Here our study clarifies human positive cofactor 4 (PC4) as a previously unrecognized RNA binding protein (RBP), as a post-transcriptional master regulator to orchestrate CCND1 and CENPF expression. We reveal that lack of PC4 reduces CCND1 stability whereas enhances excessive CENPF translation, results in cell cycle arrest and mitotic defects. Furthermore, PC4 RNA binding activity is strictly controlled by S17 phosphorylation and K68 ubiquitination in a cell cycle-dependent way. Lastly, we use in vivo model to verify that PC4 deficiency amplifies response of cancer cells to CDK4/6 inhibitor, and PC4 induction accelerates liver regeneration after partial hepatectomy. These results highlight that cell-cycle gene expressions are dynamically and post-transcriptionally fine-tuned, and identify PC4 as an essential cell-cycle post-transcriptional manipulator that is profoundly applied within cancer and regeneration medicine.

INSTRUMENT(S): Thermo Scientific instrument model

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Hepatocyte, Liver

DISEASE(S): Liver Cancer

SUBMITTER: Qimei Pan  

LAB HEAD: Chunmeng Shi

PROVIDER: PXD033637 | Pride | 2024-02-03

REPOSITORIES: Pride

Similar Datasets

2020-03-04 | PXD011374 | Pride
| PRJNA140799 | ENA
2022-02-17 | PXD027844 | Pride
2023-03-11 | PXD025399 | Pride
2023-03-11 | PXD025559 | Pride
2023-03-11 | PXD025076 | Pride
2021-11-30 | PXD029994 | Pride
2019-06-17 | PXD012514 | Pride
2024-02-22 | PXD042038 | Pride
2021-08-23 | PXD022757 | Pride